Clinical trial NCT05329051: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
Official title: A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged ≥18 Years and Previously Fully Vaccinated With mRNA COVID-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: SARS-CoV-2 Infection
COVID-19
Keywords: SARS-CoV-2
COVID-19
vaccine
Lead sponsor: Sinocelltech Ltd.
Sponsor class: INDUSTRY
First posted: 2022-04-14
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with Comirnaty.

Detailed description: Approximately 400 participants aged ≥18 years old and previously vaccinated with 2 or 3 doses of Comirnaty will be enrolled in this study. They will be randomly assigned to SCTV01E Group and Comirnaty Group in a ratio of 1:1.

Eligibility criteria: Inclusion Criteria:

Participants are eligible to be included in the study only if the following conditions are met:

1. Male or female aged ≥18 years old when signing ICF;
2. Participants who were fully vaccinated with 2 or 3 doses of mRNA COVID-19 vaccine (Comirnaty). The interval between the last dose and this study vaccination is 4 to 12 months;
3. The participant and/or his entrusted person can sign written ICF, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial;
4. The participant and/or his entrusted person has the ability to read, understand, and fill in record cards;
5. Healthy participants or participants with pre-existing medical conditions who are in stable condition. The "pre-existing medical conditions" include but not limited to hypertension, diabetes, chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. A stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment;
6. Fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the study vaccination; the pregnancy test results of women of childbearing potential are negative on screening.

Exclusion Criteria:

A participant who conforms to any of the following criteria should be excluded from the study:

1. Presence of fever within 3 days before the study vaccination;
2. A positive result of nucleic acid test for SARS-CoV-2 during the screening period or previously diagnosed with COVID-19;
3. A history of infection or disease related to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or other disease with corresponding use of immunosuppressants;
4. A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
5. A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
6. Immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including Guillain-Barre Syndrome \[GBS\], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc.;
7. Long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment. Whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed;
8. Patients on antituberculosis therapy;
9. Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia;
10. Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
11. Participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study;
12. Participants who received other investigational drugs within 1 month before the study vaccination;
13. Participants who is at the acute stage of illness, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;
14. Participants received other drugs or vaccines used to prevent COVID-19, but participants previously received Comirnaty will not be excluded;
15. Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;
16. Those who donated blood or had blood loss (≥450 mL) within 3 months before the vaccination or plan to donate blood during the study period;
17. Those who are pregnant or breast-feeding or plan to be pregnant during the study period;
18. Those who plan to donate ovum or sperms during the study period;
19. Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
20. Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
21. Those who are tested positive for HIV in terms of serology.

Primary outcomes:
measure: Geometric mean titers (GMT) of neutralizing antibodies (nAb) to Omicron variant on Day 28
timeFrame: day 28 sfter the study vaccination
measure: GMT of nAb to variant Delta on Day 28
timeFrame: day 28 sfter the study vaccination
Secondary outcomes:
measure: GMT of nAb to Alpha variant on Day 28
timeFrame: day 28 sfter the study vaccination
measure: GMT of nAb to Beta variant on Day 28
timeFrame: day 28 sfter the study vaccination
measure: Number of IFN-γ positive (characterizing Th1) and IL-4 positive (characterizing Th2) T cell subsets on Day 28.
timeFrame: day 28 sfter the study vaccination
measure: Seroresponse rates of nAb to Omicron variant on D28
timeFrame: day 28 after the study vaccination
measure: Seroresponse rates of nAb to Delta variant on D28
timeFrame: day 28 after the study vaccination
measure: Seroresponse rates of nAb to Alpha variant on D28
timeFrame: day 28 after the study vaccination
measure: Seroresponse rates of nAb to Beta variant on D28
timeFrame: day 28 after the study vaccination
measure: Incidence and severity of solicited AEs from Day 0 to Day 7 after the study vaccination
timeFrame: day 0 to day 7 after the study vaccination
measure: Incidence and severity of unsolicited AEs from Day 0 to Day 28 after the study vaccination
timeFrame: day 0 to day 28 after the study vaccination
measure: Incidence and severity of SAEs and AESIs within 180 days after study vaccination
timeFrame: day 0 to day 180 after the study vaccination
Other outcomes:
Locations:
Study officials:
References: